[{"id":"2cd0bb28-fe10-4b8b-9287-18ad8a95d0b3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03990233","created_at":"2025-06-28T13:37:59.942Z","updated_at":"2025-06-28T13:37:59.942Z","phase":"Phase 1","brief_title":"A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours","source_id_and_acronym":"NCT03990233","lead_sponsor":"OSE Immunotherapeutics","biomarkers":" SIRPA","pipe":"","alterations":" ","tags":["SIRPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezabenlimab (BI 754091) • BI 765063"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 04/16/2019","start_date":" 04/16/2019","primary_txt":" Primary completion: 04/17/2023","primary_completion_date":" 04/17/2023","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2025-06-26"},{"id":"89ce58f7-0046-45a6-9589-68bba343777d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05249426","created_at":"2024-03-27T13:37:18.528Z","updated_at":"2025-02-25T14:16:43.633Z","phase":"Phase 1","brief_title":"A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer","source_id_and_acronym":"NCT05249426","lead_sponsor":"Boehringer Ingelheim","biomarkers":" SIRPA","pipe":"","alterations":" ","tags":["SIRPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Tecentriq (atezolizumab) • paclitaxel • docetaxel • capecitabine • ezabenlimab (BI 754091) • BI 765063 • BI 836880"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 04/12/2022","start_date":" 04/12/2022","primary_txt":" Primary completion: 07/16/2024","primary_completion_date":" 07/16/2024","study_txt":" Completion: 08/02/2025","study_completion_date":" 08/02/2025","last_update_posted":"2025-02-18"},{"id":"8684fe35-4cc2-47ff-bb79-45f67ae9a6b4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05068102","created_at":"2021-10-05T20:00:16.409Z","updated_at":"2024-07-02T16:35:00.041Z","phase":"Phase 1","brief_title":"A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab","source_id_and_acronym":"NCT05068102","lead_sponsor":"Boehringer Ingelheim","biomarkers":" SIRPA","pipe":"","alterations":" ","tags":["SIRPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezabenlimab (BI 754091) • BI 765063 • BI 770371"],"overall_status":"Recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 11/16/2021","start_date":" 11/16/2021","primary_txt":" Primary completion: 01/17/2025","primary_completion_date":" 01/17/2025","study_txt":" Completion: 03/21/2025","study_completion_date":" 03/21/2025","last_update_posted":"2024-05-30"},{"id":"7bec813b-14cc-42a1-bb04-2fb83e17c553","acronym":"","url":"https://clinicaltrials.gov/study/NCT04653142","created_at":"2021-07-24T16:52:37.044Z","updated_at":"2024-07-02T16:36:10.679Z","phase":"Phase 1","brief_title":"A Study to Test Different Doses of BI 765063 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer (Solid Tumors)","source_id_and_acronym":"NCT04653142","lead_sponsor":"Boehringer Ingelheim","biomarkers":" SIRPA","pipe":"","alterations":" ","tags":["SIRPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezabenlimab (BI 754091) • BI 765063"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 12/15/2020","start_date":" 12/15/2020","primary_txt":" Primary completion: 04/20/2022","primary_completion_date":" 04/20/2022","study_txt":" Completion: 04/20/2022","study_completion_date":" 04/20/2022","last_update_posted":"2022-05-10"}]